Compare IH & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | PMVP |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.1M | 76.8M |
| IPO Year | 2020 | 2020 |
| Metric | IH | PMVP |
|---|---|---|
| Price | $1.70 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.5K | ★ 407.3K |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.55 | $0.90 |
| 52 Week High | $3.60 | $1.88 |
| Indicator | IH | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 36.62 |
| Support Level | $1.55 | $1.09 |
| Resistance Level | $1.83 | $1.26 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 25.69 | 10.00 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.